Neoadjuvant Trastuzumab and Pertuzumab Plus Chemotherapy Versus T-DM1 and Pertuzumab in HER2 Breast

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

ADAPT: de-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel in HR-/HER2+ eBCПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

HER2 Heterogeneity and Response to Neoadjuvant T-DM1 Plus PertuzumabПодробнее

Phase 3 Trial Investigates T-DM1 and Pertuzumab in HER2+ Breast CancerПодробнее

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-posi...Подробнее

Neoadjuvant T-DM1 in HER2+ Early Breast CancerПодробнее

T-DM1 Plus Pertuzumab in the MARIANNE TrialПодробнее

Which Chemotherapy With Adjuvant Trastuzumab and Pertuzumab?Подробнее

Breast Cancer: Adding Pertuzumab as a Neoadjuvant Treatment OptionПодробнее

Dr. Tripathy on Neoadjuvant Treatment Strategies in HER2+ Breast CancerПодробнее

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HE...Подробнее

Dr. Pegram on Pertuzumab and Trastuzumab in Breast CancerПодробнее

Dr. Yee on Neoadjuvant Pertuzumab in HER2-Positive Breast CancerПодробнее

Paclitaxel With Pertuzumab Plus Trastuzumab in Metastatic Breast CancerПодробнее

Dr. Mark Pegram on Combining Trastuzumab and PertuzumabПодробнее

Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancerПодробнее

INNOVATION: chemotherapy with trastuzumab and pertuzumab in HER2+ gastric cancerПодробнее

Dr. Pegram on Pertuzumab Plus Trastuzumab and Chemotherapy in Breast CancerПодробнее